Hu Zhuoyu, Chen Xiangdong, Hu Qi, Zou Menglong, Liu Zhimin
The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
Graduate School of Hunan University of Chinese Medicine, Changsha, Hunan, China.
Pharmacol Res Perspect. 2025 Apr;13(2):e70077. doi: 10.1002/prp2.70077.
Dry eye disease (DED) is a chronically inflammatory ocular surface disorder of unknown pathogenesis. Anti-inflammatory medications, artificial tears, autologous serum, and LipiFlow have been shown to be highly beneficial in alleviating symptoms. Nevertheless, these interventions often provide only short-term results and do not address the underlying problems of the disease. There is growing evidence that the risk of DED is associated with a vicious cycle of inflammation. This vicious cycle of inflammation is produced by the interaction of several factors, including tear film hyperosmolarity, tear film instability, inflammation, and apoptosis. Chinese medicine monomers, distinguished by their multicomponent and multitarget advantages, have been shown to help treat DED by modulating tear film status, and inhibiting inflammatory responses, and apoptosis, providing a new way of thinking of the management of DED in Chinese medicine.
干眼症(DED)是一种发病机制不明的慢性炎症性眼表疾病。抗炎药物、人工泪液、自体血清和Lipiflow已被证明在缓解症状方面非常有效。然而,这些干预措施往往只能提供短期效果,无法解决该疾病的根本问题。越来越多的证据表明,干眼症的风险与炎症的恶性循环有关。这种炎症恶性循环是由多种因素相互作用产生的,包括泪膜高渗、泪膜不稳定、炎症和细胞凋亡。中药单体以其多成分、多靶点的优势而著称,已被证明可通过调节泪膜状态、抑制炎症反应和细胞凋亡来帮助治疗干眼症,为中医治疗干眼症提供了新的思路。